Skip Navigation LinksHome > November/December 2013 - Volume 8 - Issue 6 > Surgical Minimally Invasive Pulmonary Vein Isolation for Lon...
Innovations: Technology & Techniques in Cardiothoracic & Vascular Surgery:
doi: 10.1097/IMI.0000000000000029
Original Articles

Surgical Minimally Invasive Pulmonary Vein Isolation for Lone Atrial Fibrillation: Midterm Results of a Multicenter Study

De Maat, Gijs E. BSc*†; Pozzoli, Alberto MD*‡; Scholten, Marcoen F. MD, PhD§; Hillege, Hans L. MD, PhD; Van Gelder, Isabelle C. MD, PhD; Alfieri, Ottavio R. MD, PhD; Benussi, Stefano MD; Mariani, Massimo A. MD, PhD*

Collapse Box


Objective: Minimally invasive surgical pulmonary vein isolation (SMI-PVI) is an emerging therapy for the treatment of symptomatic drug-refractory atrial fibrillation (AF). Nevertheless, the midterm and long-term results of SMI-PVI remain unknown. The aim of this retrospective multicenter study was to report on midterm efficacy and safety of SMI-PVI.

Methods: The study design was retrospective, multicentric, and observational. From July 2005 to November 2011, a total of 86 patients with drug-refractory paroxysmal or persistent AF underwent SMI-PVI in three centers. Patients were eligible for SMI-PVI if they had symptomatic, drug-refractory AF or after failed transcatheter pulmonary vein isolation. Success was defined as absence of AF on 24- or 96-hour Holter monitoring during follow-up, in the absence of antiarrhythmic drugs (AADs).

Results: The mean ± SD age was 54 ± 11 years, and 78% were men. The median AF duration was 30 months (range, 2-203); paroxysmal AF was present in 86% of the patients, persistent in 14%. Fifteen patients (17%) underwent previous transcatheter ablations. After a median follow-up of 24 months (range, 6-78), 72% of all patients were free from atrial arrhythmias without the use of AADs. With AADs, this was 83%. Major perioperative adverse events occurred in 7 patients (8%).

Conclusions: This retrospective multicenter study shows that SMI-PVI is effective at a median follow-up of 24 months for the treatment of mostly paroxysmal drug-refractory AF. Perioperative adverse events do remain a point of caution.

©2013 by the International Society for Minimally Invasive Cardiothoracic Surgery


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.